Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...
How the three-time Olympic medalist became freestyle skiing's biggest star ...
Green means go…to the doctor In A Nutshell Scientists engineered living skin that glows green when it detects inflammation in ...
In A Nutshell Men have double the odds of presenting with stage III multiple myeloma compared to women, even after accounting ...
Implanted living skin-based biosensors offer a breakthrough in inflammation tracking, providing real-time biomarker ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission - including an outpatient dosing option using a single weight-based dose IND amendment ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people ...